nach oben

Erschienen in:

01.12.2010 | PRECLINICAL STUDIES

Antimetastatic activity of MONCPT in preclinical melanoma mice model

verfasst von: Xiao-Chun Yang, Chong-Xing Tu, Pei-Hua Luo, Hong Zhu, Di-Feng Zhu, Hong-Hai Wu, Xing-Lu Zhou, Wei Lu, Qiao-Jun He, Bo Yang

Erschienen in: Investigational New Drugs | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Summary

Previous study demonstrated that MONCPT, a topoisomerase I inhibitor, exhibited potent anti-proliferation and anti-angiogenesis activity in vitro and in vivo. In this study, we report the efficacy of MONCPT against the development of melanoma metastasis by an intravenous injection of green fluorescent protein-transfected mice melanoma carcinoma (B16F10-GFP) cells in C57BL/6 mice. MONCPT (2.0, 5.0 and 12.5 mg/kg/2 days) markedly decreased B16F10-GFP pulmonary metastases by 12.8%, 53.1% and 76.3%, respectively; whereas higher doses of MONCPT (31.0 mg/kg/2 days) significantly inhibited the tumor growth of B16F10 xenograft model. In the in vitro experiment, MONCPT suppressed the B16F10-GFP cell invasion and migration without affecting cell survival. Further studies demonstrated that MONCPT decreased the secretion of matrix metalloproteinase (MMP)-9 and VEGF, and reduced the protein expression of HIF-1α as well as the phosphorylation level of ERK in B16F10-GFP cells. These in vivo and in vitro results indicate that MONCPT possesses both the potent antimetastatic ability and the tumor growth-inhibition activity, and the dual function promises MONCPT as a potential therapeutic agent for tumor metastasis and tumor growth of melanoma carcinoma.

Nur mit Berechtigung zugänglich

Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2(8):563–572CrossRefPubMed

Brinckerhoff CE, Matrisian LM (2002) Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 3(3):207–214CrossRefPubMed

Zucker S, Vacirca J (2004) Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 23:101–117CrossRefPubMed

Hofmann UB, Houben R, Brocker EB, Becker JC (2000) Matrix metalloproteinases in human melanoma. J Invest Dermatol 115(3):337–344CrossRefPubMed

Rao JS (2003) Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3(7):489–501CrossRefPubMed

Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25(1):9–34CrossRefPubMed

Cuvier C, Jang A, Hill RP (1997) Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L 1 B)secretion. Clin Exp Metastasis 15:19–25CrossRefPubMed

Young SD, Marshall RS, Hill RP (1988) Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci 85:9533–9537CrossRefPubMed

Rofstad EK, Danielsen T (1999) Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis. Br J Cancer 80(11):1697–1707CrossRefPubMed

10.

Semenza GL (2001) Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 7:345–350CrossRefPubMed

11.

Weidemann A, Johnson RS (2008) Biology of HIF-1alpha. Cell Death Differ 15:621–627CrossRefPubMed

12.

Semenza G (2002) Singal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 64:993–998CrossRefPubMed

13.

Dor Y, Porat R, Keshet E (2001) Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol 280:C1367–C1374PubMed

14.

Risau W (1997) Mechanisms of angiogenesis. Nature (Lond) 386:671–674CrossRef

15.

Carmeliet P, Dor Y et al (1998) Role of HIF-1 in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature 394:485–490CrossRefPubMed

16.

Canning MT, Postovit LM, Clarke SH et al (2001) Oxygen-mediated regulation of gelatinase and tissue inhibitor of metalloproteinases-1 expression by invasive cells. Exp Cell Res 267:88–94CrossRefPubMed

17.

Sun B, Zhang D, Zhang S, Zhang W, Guo H, Zhao X (2007) Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett 249(2):188–197CrossRefPubMed

18.

Luo P, He Q, He X, Hu Y, Lu W, Cheng Y, Yang B (2006) Potent antitumor activity of 10-methoxy-9-nitrocamptothecin. Mol Cancer Ther 5:962–968CrossRefPubMed

19.

Yang X, Luo P, Yang B, He Q (2006) Antiangiogenesis response of endothelial cells to the antitumour drug 10-methoxy-9-nitrocamptothecin. Pharmacol Res 54(5):334–340CrossRefPubMed

20.

Wong ET, Berkenblit A (2004) The role of topotecan in the treatment of brain metastases. Oncologist. 9(1):68–79CrossRefPubMed

21.

Shimada S, Hayashi N et al (2002) Irinotecan plus low-dose cisplatin for α-fetoprotein-producing gastric carcinoma with multiple liver metastases: report of two cases. Surg Today 32:1075–1080CrossRefPubMed

22.

Douillard JY, Cunningham D et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209):1041–1047CrossRefPubMed

23.

Wani MC, Nicholas AW, Wall ME (1986) Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues. J Med Chem 29:2858–2863CrossRef

24.

Yang B, Reynolds CP (2005) Tirapazamine cytotoxicity for neuroblastoma is p53 dependent. Clin Cancer Res 11:2774–2780CrossRefPubMed

25.

Skehan P, Storeng R, Scudiero D et al (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107–1112CrossRefPubMed

26.

Zhu H, Huang M et al (2007) R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II. Mol Cancer Ther 6(2):484–495CrossRefPubMed

27.

Zhang J, Shen Y, Liu J, Wei D (2005) Antimetastatic effect of prodigiosin through inhibition of tumor invasion. Biochem Pharmacol 69(3):407–414CrossRefPubMed

28.

Nakagawa K, Sasaki Y, Kato S, Kubodera N, Okano T (2005) 22-Oxa-1alpha, 25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 26(6):1044–1054CrossRefPubMed

29.

Huang Q, Shen HM, Ong CN (2004) Inhibitory effect of emodin on tumor invasion through suppression of activator protein-1 and nuclear factor-kappaB. Biochem Pharmacol 68(2):361–371CrossRefPubMed

30.

Ying M, Tu C, Ying H, Hu Y, He Q, Yang B (2008) MSFTZ, a flavanone derivative, induces human hepatoma cell apoptosis via a reactive oxygen species- and caspase-dependent mitochondrial pathway. J Pharmacol Exp Ther 325(3):758–765CrossRefPubMed

31.

Yang M, Jiang P et al (1999) Genetically fluorescent melanoma bone and organ metastasis models. Clin Cancer Res 5(11):3549–3559PubMed

32.

Vihinen P, Kahari VM (2002) Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99(2):157–166CrossRefPubMed

33.

Ho LL, Chen WJ, Lin-Shiau SY, Lin JK (2002) Penta-O-galloyl-beta-Dglucose inhibits the invasion of mouse melanoma by suppressing metalloproteinase-9 through down-regulation of activator protein-1. Eur J Pharmacol 453(2–3):149–158CrossRefPubMed

34.

Ellerbroek SM, Halbleib JM, Benavidez M, Warmka JK, Wattenberg EV, Stack MS et al (2001) Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res 61(5):1855–1861PubMed

35.

Westermarck J, Kahari VM (1999) Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13(8):781–792PubMed

36.

Bischof P, Meisser A, Campana A (2002) Control of MMP-9 expression at the maternal-fetal interface. J Reprod Immunol 55(1–2):3–10CrossRefPubMed

37.

Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK (2001) Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor1. Cell Growth Differ 12:363–369PubMed

38.

Hur E, Chang KY, Lee E, Lee SK, Park H (2001) Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1alpha. Mol Pharmacol 59:1216–1224PubMed

39.

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70CrossRefPubMed

40.

Tiwari A, Kumar N, Bajpai R, Lal P (2007) Bone metastasis from ovarian cancer. J Cancer Res Ther 3(1):34–36CrossRefPubMed

41.

Papadimitriou CA, Fountzilas G et al (2008) Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. Gynecol Oncol 111(1):27–34 Epub 2008 Jul 21CrossRefPubMed

42.

Yang M et al (2000) Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc Natl Acad Sci 97(3):1206–1211CrossRefPubMed

43.

Hoffman R et al (2002) Green fluorescent protein imaging of tumour growth, metastasis, and angiogenesis in mice models. Lancet Oncol 3(9):546–556CrossRefPubMed

44.

Paris S, Sesboüé R (2004) Metastasis models: the green fluorescent revolution? Carcinogenesis 25(12):2285–2292CrossRefPubMed

45.

Bogenrieder T, Herlyn M (2003) Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22:6524–6536CrossRefPubMed

46.

Nabeshima K, Inoue T, Shimao Y, Sameshima T (2002) Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 52:255–264CrossRefPubMed

47.

Abiru S, Nakao K, Ichikawa T, Migita K, Shigeno M, Sakamoto M et al (2002) Aspirin and NS-398 inhibit hepatocyte growth factorinduced invasiveness of human hepatoma cells. Hepatology 35:1117–1124CrossRefPubMed

48.

Shao ZM, Wu J, Shen ZZ, Barsky SH (1998) Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res 58:4851–4857PubMed

49.

Reddy KB, Nabha SM, Atanaskova N (2003) Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 22(4):395–403CrossRefPubMed

50.

Qiao M, Sheng S, Pardee AB (2008) Metastasis and AKT activation. Cell Cycle 7(19):2991–2996 Epub 2008 Oct 13PubMed

Titel: Antimetastatic activity of MONCPT in preclinical melanoma mice model
verfasst von: Xiao-Chun Yang
Chong-Xing Tu
Pei-Hua Luo
Hong Zhu
Di-Feng Zhu
Hong-Hai Wu
Xing-Lu Zhou
Wei Lu
Qiao-Jun He
Bo Yang
Publikationsdatum: 01.12.2010
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 6/2010
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-009-9323-8

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Antimetastatic activity of MONCPT in preclinical melanoma mice model

Summary

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2010

Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes

DH9, a novel PPARγ agonist suppresses the proliferation of ADPKD epithelial cells: An association with an inhibition of β-catenin signaling

Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations

Erratum to: Antimetastatic activity of MONCPT in preclinical melanoma mice model

The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie